American Society of Gene & Cell Therapy
Annual Meeting
Salt Lake City, Utah USA
May 15-18, 2013

Call for Abstracts
Submissions Open: November 1, 2012
Deadline for Submissions: January 14, 2013
Call for Abstracts

Submissions Open: November 1, 2012
Deadline for Submissions: January 14, 2013

ASGCT
Through its educational programs and services, ASGCT strives to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapeutics to alleviate human disease.

MEETING INFORMATION
ASGCT’s Annual Meeting is the primary forum for the Society to serve as a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

The ASGCT 16th Annual Meeting will take place May 15-18, 2013 in Salt Lake City, Utah, USA.

The target audience includes basic science and translational researchers, clinical investigators, physicians, postdoctoral fellows, graduate students, other healthcare professionals and employees of federal government and regulatory agencies, academic institutions and the biotechnology industry with an interest in the latest advancements in the field of gene and cellular therapies.

GENERAL INFORMATION
The abstract submission site will go live at www.asgct.org on November 1, 2012

Abstract submission deadline: January 14, 2013 at 6:00 PM EST.

- Over 225 (25%) of the abstracts submitted by the above deadline will be eligible for oral presentations based on their review score and the determination of the Abstract Review Committees. The Committees will also determine where abstracts will be placed within the program.
- All accepted abstracts will be published in a supplement to Molecular Therapy, which will be distributed at the ASGCT Annual Meeting, as well as on the ASGCT website. Accepted abstracts will go live on the ASGCT website (www.asgct.org) beginning April 18, 2013 at 12:00 PM EDT.
- There is no fee to submit an abstract.

To begin the submission process, please go directly to http://www.call4abstracts.com/asgct/

ELIGIBILITY
- ASGCT Members and non-members are eligible to submit an abstract.
- Submitting an abstract does not register you for the meeting. You must register for the meeting to present your abstract. Meeting registration will be available online at www.asgct.org in December 2012.

Please do not submit an abstract if you are not prepared to travel to the meeting and present it in the form selected by ASGCT.

INELIGIBILITY
- Papers that have been accepted for publication or published prior to the abstract submission deadline may not be submitted unless special consideration is requested.
- If your abstract was previously accepted for presentation at ASGCT or another national/international meeting, do not submit the abstract again, unless there is significantly more data to report.

ASSOCIATE MEMBERS
- ASGCT will be offering 120 travel grants to postdoctoral fellows and students who are Associate Members of ASGCT by the submission deadline ($500 value (North America and Mexico; $600 value International).
- 30 Associate Members will also receive funding for their poster production.

Note: Travel grants and poster funding will be awarded based on abstract review scores and a determination of the ASGCT Abstract Review Committee. Please Note: Meeting registration fees are non-reimbursable; travel grant recipients must register for the meeting and pay the registration fees.

INTERNATIONAL ABSTRACT SUBMITTERS
International abstract submitters who plan to attend the ASGCT 16th Annual Meeting will need to apply for a VISA to travel to the meeting in Salt Lake City, Utah, USA.

Please Note: The amount of time required to obtain a VISA has increased tremendously. ASGCT recommends that potential abstract presenters apply for their VISA as soon as possible, even before their abstract is submitted.

If you need an official letter from ASGCT as part of your VISA application, please contact Ken Janowski (kjanowski@asgct.org) at ASGCT.
**ABSTRACT TOPIC CATEGORIES**

When submitting an abstract, authors will select one first choice topic and one second choice topic from the list below that best describes their abstract.

**Viral Vector Development**
Vectors not specifically mentioned should be directed to the most closely related category. Hybrid vectors should be directed to the category that makes the largest contribution to the performance of the vector system.

- A1. RNA Virus Vectors
- A2. AAV Vectors
- A3. Adenovirus Vectors and Other DNA Viruses

**Synthetic Gene Delivery**

- B1. DNA Vectorology & Gene Targeting (includes gene correction strategies)
- B2. Physical Methods of Delivery
- B3. Chemical and Molecular Conjugates

**Disease Models and Clinical Applications**

- C1. Gene & Cell Therapy of Diabetes, Metabolic and Genetic Diseases - Modified Category!
- C2. Cardiovascular Gene & Cell Therapy – (includes pulmonary hypertension)
- C3. Neurologic Gene & Cell Therapy – (includes inherited, progressive and acquired diseases) – Modified Category!
- C4. Musculo-skeletal Gene & Cell Therapy – (includes inherited, progressive and acquired diseases; excludes diseases affecting lung and respiratory muscles)
- C5. Infectious Diseases and Vaccines – (excludes respiratory infectious diseases)
- C9. Hematologic and Immunologic Gene & Cell Therapy – (excludes leukemia or lymphoma)
- C10. Gene and Cell Therapy for Pulmonary Diseases – (includes therapy for diseases affecting the lung and respiratory muscles, direct pulmonary gene transfer, respiratory infections, and lung cancer)
- C11. Immunologic & Host Responses in Gene & Cell Therapy

**Gene Regulation**

- D. Gene Regulation – (includes gene expression, animal model systems and gene modification)

**Oligonucleotide Therapies**

- E. Oligonucleotide & RNAi Therapeutics – (includes RNAi and shRNA)

**Stem Cell Therapies**

- F. Stem Cell Therapies – (includes somatic and embryonic technologies)

**Cell Processing and Vector Production**

- G. Cell Processing and Vector Production

---

**NOTIFICATION OF ABSTRACT ACCEPTANCE AND AWARDS**

Notification regarding acceptance or non-acceptance of abstracts will be made in mid-March 2013 via email, with official letters being made available online for download. Travel Grant and Excellence in Research Award acceptance and non-acceptance letters will also be sent at this time.

**ACCEPTANCE OF PRESENTATION**

All notified abstract presenters are required to accept their presentation as instructed in their notification email. This will be available online through the abstract submission site.

---

**LATE BREAKING ABSTRACT SUBMISSIONS**

ASGCT will offer a late breaking abstract submission process. Late breaking abstracts MUST be of high quality, represent an important research advancement and present information that was not available at the time of regular abstract submission.

The submission site for late abstracts will open on March 1, 2013. The deadline for late breaking submissions will be March 25, 2013.

**PLEASE NOTE:**

- **No travel awards** will be given for late breaking abstract submissions.
- **Only up to eight** (8) late breaking abstract submissions will be eligible for oral presentations based on their scores and the determination of the review committee. The Committee will not award oral presentations if it is deemed the abstracts are not late breaking.
- The remaining accepted late breaking submissions will be scheduled as poster presentations.
- Do not submit a late breaking abstract if it is a revision of an abstract submitted during the original submission process.

---

**ABSTRACT QUESTIONS**

For all questions regarding the abstract submission process, please contact Coe-Truman Technologies’ Technical Support by phone at 1-507-403-2305 or by email at c4asupport@coetruman.com. For changes to abstracts already submitted, please email changes@coetruman.com.

Technical Support is open Monday – Friday during the following hours:

- 9:00 am – 6:00 pm EST
- 8:00 am – 5:00 pm CST
- 7:00 am – 4:00 pm MST
- 6:00 am – 3:00 pm PST